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Introduction: Previous studies have shown that interleukin-6 (IL-6) levels correlated with mortality in
critically ill patients.
Goal: To determine the effect of ketamine on IL-6 levels in liver resections patients with a temporary
porto-arterial occlusion (Pringle manoeuvre).
Materials and methods: Controlled, prospective, randomized, double-blinded study. One group
(n = 21) received ketamine whereas the other group (n = 17) received placebo. IL-6 levels were obtained
at baseline, 4, 12, 24 h, 3 and 5 days.
Results: There were no significant differences in IL-6 levels between the groups (basal P = 089, 4 h
P = 0.83, 12 h P = 0.39, 24 h, P = 0.55, 3 days P = 0.80 and 5 days P = 0.45). Both groups had elevated
IL-6 levels that became almost undetectable by day 5. There was no major morbidity and no mortality in
either group.
Conclusions: Ketamine does not seem to have an effect on plasma levels of IL-6. This could be
interpreted as a potential finding associated with outcome as we did not encounter any deaths or major
complications. Further studies will likely be needed to determine the range of IL-6 levels associated with
survival and mortality, and whether it could be a predictor of survival.
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Introduction
The modern surgical era of liver surgery began in 1952 when
Lortat-Jacob reported the first surgical resection of a liver
tumour.1 More than two decades later, in 1977, the first multicen-
tre study with 621 hepatectomies established guidelines2 but the
overall intra-operative mortality rate was 13%, with a rate exceed-
ing 20% formajor resections.Most deaths and complications were
attributable to surgical haemorrhage. By the 1990s,mortality rates
had decreased to 5% or less,3,4 and over half of all resections
involved colorectal liver metastases.5 Surgery was found to provide
a better survival than chemotherapy alone for both primary and
metastatic lesions, and provided the only potentially for a cure.5,6
Although improvements in surgical and anaesthetic techniques
have improved outcomes,7 an intra-operative haemorrhage
and post-operative liver failure remain the two most feared
DOI:10.1111/j.1477-2574.2011.00357.x HPB
HPB 2011, 13, 706–711 © 2011 International Hepato-Pancreato-Biliary Association
complications.8 Hepatic insufficiency can result either from a
remnant liver volume unable to satisfy the physiological demands
of the body, or from a surgical trauma-induced inflammatory
process that leads to progressive cellular demise.
Two intra-operative manoeuvres that can potentially reduce
blood loss during liver resections are total hepatic vascular occlu-
sion and porto-arterial inflow occlusion (the Pringle manoeu-
vre).9 The latter, in the setting of low central venous pressure
(CVP), has provided superior outcomes to the point of even com-
pletely avoiding blood transfusions.10 These manoeuvres,
however, may lead to ischaemia/reperfusion (I/R) and activation
of leukocytes and Kupffer cells.
Activated leukocytes within the hepatic vasculature generate
cytokines that amplify the inflammatory mechanisms, weaken the
immune response and lead to unpredictable outcomes.11 In severe
cases, cell death can cause post-operative multi-organ failure as a
result of the local and systemic effect of cytokines.12–14
Hepatic trauma, as well as liver resection and transplantation
are characterized by an initial period of I/R followed by an inflam-
matory response that can be associated with significant tissue
injury. Interleukin-6 (IL-6), one of the major cytokines encoun-
tered in inflammation and cancer, has been implicated in post-
surgical cellular damage when present in high concentrations.15 It
has also been found to be involved with hepatic tissue repair.15–18
Over the past decade, researchers working mostly in vitro and
with animal models, have attempted to further evaluate the effect
of IL-6 on hepatic regeneration and growth after tissue loss.19
Previous studies attempted to minimize the production of free
radicals and IL-6 in an effort to minimize cell death. In cardiac
interventions with cardiopulmonary bypass, administration of
low doses of ketamine was found to be associated with decreased
IL-6 levels over the ensuing days. It remained unclear, however,
whether this finding was associated with a decrease in morbidity
and mortality.20
Ketamine, a widely used anaesthetic agent, has been postulated
as an inhibitor of IL-6 synthesis in procedures with a significant
pro-inflammatory response, such as in cardiac surgery with car-
diopulmonary bypass.20–26
The purpose of the present study was to evaluate the effect of
ketamine on IL-6 synthesis in hepatic resections requiring tem-
porary porto-arterial occlusion (the Pringle manoeuvre).
Materials and methods
This prospective, controlled, randomized, double-blinded study
was approved by the Research Ethics Committee of the Hospital
Italiano of Buenos Aires (CEPI) and carried out according to the
Declaration of Helsinski. All patients voluntarily consented to the
study and signed the appropriate informed consent approved by
the CEPI.
Inclusion criteria were age of 21 years or older and planned liver
resection with the Pringle manoeuver lasting 30–60 min. Those
with chronic illnesses requiring corticosteroids, cirrhosis, haemo-
dynamic instability before the surgery, diabetes, sepsis, surgical
interventions or chemotherapy treatment within the past 30 days,
pregnancy, illness that could potentially affect the hepatic circu-
lation, arterial or ocular hypertension (contraindications for the
use of ketamine), a ketamine allergy, pre-operative portal
embolization/radiofrequency ablation or requiring emergency
surgeries were not included in the present study. From March
2002 to June 2008, 44 consecutive patients agreed to participate
and were enrolled in the study. Those who did not require the
Pringle manoeuver during the resection, as well as those who did
not undergo the planned procedure or whose haematocrit was less
than 20% for over 30 min, were excluded from the present study.
Patients were assigned to one of two groups according to
computer-generated randomization. The study group received
ketamine 0.25 mg/kg, whereas the control group was adminis-
tered an identical volume of saline. Syringes containing 10 ml of
either ketamine or saline were delivered by hospital pharmacy
personnel to the anaesthesiologist, who was blinded to their con-
tents. To calculate the correct dose that was administered imme-
diately after induction of anaesthesia, the ketamine (placebo)
concentration was established at 10 mg/ml. All cases involved the
same anaesthesia and surgical teams. Members of both teams as
well as all personnel involved with blood collection remained
blinded at all times.
All patients were transported to the operating room with an
intravenous (i.v.) line in place and premedicated with midazolan
0.04 mg/kg. Once in the operating room, they received i.v. antibi-
otics, invasive cardiac monitoring, blood pressure monitoring and
pulse oxymetry. Remifentanil 0.25 mg/kg/min was administered
before induction with sodium thiopental 2–2.5 mg/kg. Vecuro-
nium 0.1 mg/kg was used for muscle relaxation. After waiting
approximately 3 min, patients were endotracheal intubated and a
nasogastric tube was placed. Remifentanil 0.5 mg/kg/min, ibupro-
fen 10 mg/kg and morphine 0.15 mg/kg were administered. Ana-
esthesia was maintained with sevorane in the setting of an FiO2 of
0.70. Mechanical ventilation was adjusted to allow an EtCO2 of
25–30 mmHg and a plateau pressure < 30 cmH2O.An arterial line
was placed after induction of anaesthesia for invasive monitoring
as well as for blood sampling. A central line was placed in the right
internal jugular vein to monitor intra-operative central venous
pressure (CVP). All patients received body warmers and warmed
fluids. A target CVP of <5 cm H2O was sought at the time of
resection to diminish bleeding. Intravenous 10- to 20-mg doses of
furosemide as well as fluid restriction were utilized when neces-
sary to reach the desired parameters. Potassium levels were kept at
or above 3.5 mEq/l. Phenylephrine was used when necessary to
maintain a median arterial pressure of at least 70 mmHg.
Patients who underwent extensive resections were admitted to
the intensive care unit (ICU) and maintained on mechanical
ventilation for 6–8 h before extubation. All other patients
were extubated at the end of the procedure, observed in the
post-anaesthesia care unit (PACU) for at least 8 h and subse-
quently transferred to the ward area if haemodynamically stable.
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Pain management in patients extubated intra-operatively was
with synthetic opioids (dextropopoxifen 1 mg/kg and dipyrone
2.5 mg). In cases of persistent pain (4 or more in a visual scale of
10), analgesia was supplemented with 2 mg of morphine every
20 min until relief of symptoms, somnolence or a respiratory rate
8 per min was observed.
Blood samples for IL-6 levels were obtained before surgery,
upon placement of the first intravenous line, at 4 and 12 h after
the Pringle manoeuver, on the 3rd and on the 5th postoperative
days. In all cases peripheral venous blood was sampled at a site
where no contamination with any of the infused fluids could
occur. Immediately after obtaining the sample, the blood was
centrifuged, the serum isolated and frozen to -70°C. In all cases,
two plasma tubes of each sample were individually labelled and
stored.
IL-6 was quantified by means of the IL-6 ELISA (Biosource,
Europe Belgium) based on oligoclonal antibodies coupled with
monoclonal antibodies to various IL-6 epitopes. This method
showed both low and standard IL-6 range sensitivity. The results
expressed represent the mean of both samples obtained at each
time point.
Statistical analysis
Based on previous studies that reported >100 pg/ml difference
among both groups with a standard deviation (SD) < 50 pg/ml,
we based our calculations on a predicted difference among both
groups of 50 pg/ml with a SD of 50 pg/ml.17 A total of 36 patients
were randomized based on the observation that 16 patients in
each group would allow rejection of the null hypothesis with an
80% confidence in the setting of a difference >50 pg/ml. P < 0.05
was considered significant.
Results
Forty-two patients enrolled in the study. Of these, 4 (3 in the
placebo and 1 in the ketamine group) were excluded because no
Pringle manoeuver was undertaken during the hepatic resection.
Thus, 38 patients, 21 (55.3%) in the ketamine group and 17
(44.7%) in the placebo arm, were considered in our analysis.
Demographic and clinical characteristics of all patients are
described in the CONSORT diagram (Fig. 1) as well as in Table 1.
All patients underwent surgery without major complications, and
were discharged in a stable condition.
Placebo group: Males n = 12,
                         Females n = 8
Ketamine group: Males n = 12,
                           Females n = 10
A: 1 patient with haematocrit <20% for >30 minutes during surgery.
     2 patients did not require Pringle manaeuver.
B: 1 patient did not undergo the planned surgical procedure
Patients evaluated n = 44
Randomized n = 42
Did not fulfill criteria n = 2
Refused to participate n = 0
Other reasons n = 0
Analysed n = 17
Excluded from analysis n = 0
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Assigned to intervention n = 20
Underwent intervention n = 17
Did not undergo intervention n = 3
Reason: Please refer to A
Lost to follow-up n = 0
Intervention discontinued n = 0
Lost to follow-up n = 0
Intervention discontinued n = 0
Analysed n = 21
Excluded from analysis n = 0
Assigned to intervention n = 22
Underwent intervention n = 21
Did not undergo intervention n = 1
Reason: Please refer to B 
Figure 1 CONSORT diagram detailing the study. Placebo group: males n = 12, memales n = 8. Ketamine group: males n = 12, females
n = 10. (a) one patient with a haematocrit <20% for >30 min during surgery. Two patients did not require the Pringle manoeuver. (b) One
patient did not undergo the planned surgical procedure
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Evaluation showed the data distribution to be non-parametric.
A Mann–Whitney Rank Sum Test was used to compare the
groups. Table 2 shows mean SD as well as P-values for both
groups. There were no significant differences in IL-6 levels
between both groups at any of the time periods considered. The
study was based on an intention-to-treat analysis.
Figure 2 depicts IL-6 levels for both groups at the various time
intervals of the study. Although IL-6 levels in the ketamine group
showed a decline after only 4 h, the 32.4 pg/ml (95% CI 90.5–
25.6) difference among both groups was smaller than the
100 pg/ml considered as clinically relevant in our statistical
analysis.20
Discussion
Most of the very few previous reports that have addressed the
effect of ketamine on the post-operative inflammatory response
involve in vitro or laboratory animal trials. Royblat et al. who were
the first to address this topic, observed that subanaesthetic doses
of ketamine administered at induction decreased IL-6 levels in
women undergoing hysterectomies.23 In a follow-up study, the
same authors evaluated IL-6 levels in patients undergoing coro-
nary revascularization with cardiopulmonary bypass.20 Complex
surgical interventions such as surgical trauma, I/R injury and
cardiopulmonary bypass became the preferred models to evaluate
the systemic inflammatory response.
The purpose of the present study was to evaluate whether ket-
amine could lower IL-6 levels, decreasing the inflammation and
potentially lowering morbidity and mortality rates. Ketamine was
administered i.v. in doses smaller than those required to achieve
hypnosis or analgesia (0.25 mg/kg).
Almost a decade after the initial publications by Royblat et al.
similar results were observed with sub-anaesthetic doses of ket-
amine, when IL-6 and tumour necrosis factor (TNF) production
decreased with no effect on IL-2 levels. The authors concluded that
this was the result of a direct effect on IL-6 and TNF synthesis27.
In ophthalmic surgery, ketamine was not associated with
decreased cytokine concentrations even at therapeutic doses
equivalent to four times those used by Royblat et al.28 Except for a
trend in decreased leukocyte chemotaxis, ketamine had no major
effect on inflammatory changes in cultured human endothelial
cells.29 In a recent study evaluating low-risk cardiac surgery with
no cardiopulmonary bypass, low doses of ketamine had no inhibi-
tory effect on the synthesis of IL-6, TNF or C-reactive protein.
These findings, inconsistent with those of Royblat et al., could be
potentially attributed to a diminished inflammatory response
associated with the absence of a cardiopulmonary bypass, to dif-
ferent anaesthetic agents, or to the use of statins in patients with
coronary artery disease.30
The present results showed that patients who received ketamine
had slightly lowerplasma IL-6 levels than the control group at 4 and
12 h, as well as on the 2nd and 3rd days. Our groups also showed
different IL-6 kinetics after performance of the Pringlemanoeuver.
IL-6 levels peaked at 12 h in the control group and at 4 h in the
ketamine group. Concentrations were similar in both groups by
day 5. Eight patients in the control group vs. only 2 in the ketamine
group reached IL-6 levels >300 pg/ml. All eight reached their peak
4 to 24 h post-Pringle manoeuver. One of them was as high as
900 pg/ml. IL-6 levels remained elevated 4 to 12 h post Pringle
manoeuver in only one patient in the ketamine group, and had
normalized by 24 h. All patients had very low IL-6 levels after the
3rd day. In the ketamine group, levels started to decrease by 24 h.
Table 1 Demographic characteristics of both groups comparing surgical procedures, frequency of transfusions, intra-operative vascular
occlusion times and post-operative intensive care unit admissions
Ketamine (n = 21) Placebo (n = 17)
Age (year) 62  13.4 54.5  13.8 (P = 0.09)
Weight (kg) 73.5  9.1 73.3  12 (P = 0.95)
Gender M/F 13/8 M/F 11/6
Major resections n (%) 12 (60%) 11 (66%)
Duration of surgery (min) 254 (185–286) 234 (190–275)
Transfusions (n) 2/21 3/17
Duration of Pringle manoeuver w/o unclamping (min) 31 (24–37) 33 (26–36)
Total duration of Pringle manoeuver including unclamping (min) 41 (34–48) 46 (36–53)
Patients admitted to ICU (n) 12 11
w/o, without.
Table 2 Interleukin-6 (IL-6) levels (mean  SD) according to time
periods for both groups
Time period Placebo (n = 17) Ketamine (n = 21) P-value
Basal 7.71  13.21 6.86  7.08 0.89
4 h 186.71  175.87 162.98  142.7 0.83
12 h 216.43  219.75 139.39  130.66 0.39
24 h 151.29  135.38 116.14  81.65 0.55
3 days 110.17  99.12 88.24  61.5 0.80
5 days 58.23  74.41 53.92  45.4 0.46
IL-6 levels are expressed in pg/ml. Statistical analysis based on Mann–
Whitney Rank Sum Test.
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None of the IL-6 values achieved in this series resembled those in
patients with serious pathologies. Critically ill patients in septic
shock had plasma levels persistently as high as 3000 pg/ml. In these
instances, levels correlated directly with mortality. Polytrauma
patients exhibited IL-6 levels in the 600 pg/ml range, but showed
no association with clinical evolution. Levels were only higher in
the setting of superimposed infections. These differences among
septic and polytraumapatients could be attributable to themassive
inflammatory response associated with sepsis.31 When IL-6 levels
were compared among various types of surgical interventions, they
were found to be lower in orthopaedic cases and higher in colonic
surgeries where the immune challenge was greater.32 In critically ill
patients, IL-6 levels remained elevated for a prolonged period of
time and correlated not only with mortality but also with the
severity of illness as determined by predictive scores such as sepsis-
related Organ Failure Assessment (SOFA) and Acute Physiology
and Chronic Health Evaluation (APACHE) II.33,34
It would probably be difficult to determine the reasons for the
lack of the difference between both groups in the present study.
The anaesthetic drugs were identical to those used in previous
studies, and the anaesthetic technique was based on sevofluorane,
an agent that inhibits neutrophils in a dose-dependent fashion,
preventing the synthesis of cytokines.35 Morphine, used as anal-
gesic in our series, seems to have less of an inhibitory effect on
cytokines than synthetic drugs with a similar action. Recent
studies have shown that morphine can inhibit synthesis of TNF,
IL-6, and IL-10 in monocytes but not in polymorphonuclear leu-
kocytes.36 Another possible explanation could be derived from
laboratory animal studies, where ketamine in physiological con-
centrations inhibited NF-kB but had no effect on IL-6 or TNF.
Only at supra-therapeutic doses of 50 mg/kg (approximately 10
times higher than the usual i.v. dose) did ketamine inhibit all
inflammatory mediators.37 Therapeutic doses of ketamine inhib-
ited phagocytosis, production of oxygen radicals and synthesis of
cytokines without causing cell damage in murine macrophages
in vitro. These observations led to the proposal that ketamine
could have an effect on mitochondrial membrane depolariza-
tion.38 An alternate explanation is based on the fact that in the
setting of hepatic resections, IL-6 could lead to localized injury
associated with a repair mechanism rather that with a systemic
threat as seen in massive sepsis. Both groups in the present study
had elevated IL-6 levels that became almost undetectable by day 5.
The fact that IL-6 did not show elevations similar to those in
terminal patients could be interpreted as a potential finding asso-
ciated with outcome as we did not encounter any deaths or major
complications. Further studies will be needed to determine the
IL-6 range associated with survival, and whether it could represent
a predictor of outcome.
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